These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33767283)

  • 1. Age-stratified comparison of clinical outcomes between medical and surgical treatments in patients with unilateral primary aldosteronism.
    Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Watanabe M; Kamemura K; Okamura S; Tanabe A; Naruse M;
    Sci Rep; 2021 Mar; 11(1):6925. PubMed ID: 33767283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
    Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
    Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
    Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function.
    Kobayashi H; Abe M; Nakamura Y; Takahashi K; Fujita M; Takeda Y; Yoneda T; Kurihara I; Itoh H; Tsuiki M; Wada N; Ichijo T; Katabami T; Ogawa Y; Kawashima J; Yoshimoto T; Sone M; Inagaki N; Watanabe M; Kamemura K; Matsuda Y; Izawa S; Tanabe M; Tanabe A; Suzuki T; Naruse M;
    Hypertension; 2019 Sep; 74(3):630-638. PubMed ID: 31327258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
    Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
    Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
    Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
    Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.
    Watanabe D; Morimoto S; Morishima N; Ichihara A
    Endocrine; 2024 Apr; 84(1):245-252. PubMed ID: 38087188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
    Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
    Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
    Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
    High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.
    Iwakura Y; Morimoto R; Kudo M; Ono Y; Takase K; Seiji K; Arai Y; Nakamura Y; Sasano H; Ito S; Satoh F
    J Clin Endocrinol Metab; 2014 May; 99(5):1593-8. PubMed ID: 24285678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
    Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
    Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.
    Künzel HE; Apostolopoulou K; Pallauf A; Gerum S; Merkle K; Schulz S; Fischer E; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
    J Psychiatr Res; 2012 Dec; 46(12):1650-4. PubMed ID: 23017810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments.
    Wu VC; Wang SM; Huang KH; Tsai YC; Chan CK; Yang SY; Lin LY; Chang CC; Lu CC; Lin YH; Chen YM; Chueh JS
    Eur J Endocrinol; 2021 Dec; 186(2):195-205. PubMed ID: 34851859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry.
    Araujo-Castro M; Paja Fano M; González-Boillos M; Pascual-Corrales E; Martín Rojas-Marcos P; García-Cano A; Ruiz-Sanchez JG; Vicente A; Gómez-Hoyos E; Casterás A; Puig-Pérez A; García Sanz I; Recasens M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román A; Robles Lázaro C; María Recio J; Morales-Ruiz M; Calatayud M; Jiménez López N; Meneses D; Sampedro Nuñez M; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Castillo Tous MD; Serrano J; Michalopoulou T; Tenés Rodrigo S; Roa Chamorro R; Jaén Aguila F; Moya Mateo EM; Gutiérrez-Medina S; Hanzu FA; Parra Ramírez P
    J Hypertens; 2024 Oct; 42(10):1805-1812. PubMed ID: 39051487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome.
    Zhang J; Libianto R; Lee JC; Grodski S; Shen J; Fuller PJ; Yang J
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):40-46. PubMed ID: 34743353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment.
    Velema M; Dekkers T; Hermus A; Timmers H; Lenders J; Groenewoud H; Schultze Kool L; Langenhuijsen J; Prejbisz A; van der Wilt GJ; Deinum J;
    J Clin Endocrinol Metab; 2018 Jan; 103(1):16-24. PubMed ID: 29099925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age, Gender, and Body Mass Index as Determinants of Surgical Outcome in Primary Aldosteronism.
    Naruse M; Yamamoto K; Katabami T; Nakamaru R; Sone M; Kobayashi H; Tanabe A
    Horm Metab Res; 2020 Jun; 52(6):454-458. PubMed ID: 32252109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
    Marzano L; Colussi G; Sechi LA; Catena C
    Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study.
    Köhler A; Sarkis AL; Heinrich DA; Müller L; Handgriff L; Deniz S; Schneider H; Künzel H; Ladurner R; Reincke M; Adolf C
    Eur J Endocrinol; 2021 Oct; 185(5):663-672. PubMed ID: 34468397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.